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Bone metastases are common in breast cancer and may cause considerable 
morbidity including fractures, severe pain, nerve compression and hypercalcaemia. 
Alongside developments in the multidisciplinary management for patients with 
metastatic breast cancer, the use of bisphosphonates, and more recently 
denosumab, has transformed the course of advanced breast cancer for many 
patients resulting in a major reduction in skeletal complications, reduced bone pain 
and improved quality of life. Additionally, because the bone marrow 
microenvironment is so intimately involved in the metastatic processes required for 
cancer dissemination, the use of adjuvant bisphosphonates has been studied 
extensively over the past 25 years in many randomised trials.  We now have clear 
evidence that bisphosphonates significantly reduce both metastasis to bone and 
mortality in postmenopausal women with early breast cancer. Efficacy seems similar 
across different biological subgroups of postmenopausal breast cancer with the use 
of either a nitrogen-containing bisphosphonate such as intravenous zoledronate or 
daily oral ibandronate as well as the non-nitrogen containing agent, daily oral 
clodronate. In this overview of evolving role of bisphosphonates in breast cancer, 
focussing particularly on pamidronate and zoledronate, the long winding 
development road from the 1970s through to the present day is described and some 




Bisphosphonates have transformed the care of breast cancer patients with bone 
metastases and are firmly established as a key element of standard treatment 
throughout the course of the disease. 
In postmenopausal women with early breast cancer, bisphosphonates reduce bone 
recurrences by about one quarter and cancer deaths by one sixth. 
Due to limited understanding of the underlying biology of metastasis and the 
limitations of animal model systems, the clinical development of bisphosphonates in 
oncology has been relatively slow and complex and largely reliant on discoveries and 














Bisphosphonates were first synthesised in the late 19
th
 century, but initial usage was 
restricted to a range of industrial processes and their potential clinical relevance not 
appreciated until the late 1960s.
1
 Then, following a greater understanding of their 
pharmacology
2,3





 for the treatment of osteoporosis and Paget’s disease of bone, a 
few academic groups, particularly in Europe including Helsinki (Elomaa), Sheffield 
(Kanis, Russell), Leiden (Bjjvoet, Papapoulos), Brussels (Body), London (Rubens, 
Coleman), Manchester (Howell, Anderson) and Lausanne (Burckhardt, Thurlimann), 
began to investigate the potential role of bisphosphonates in cancer patients. 
Hypercalcaemia of malignancy 
The initial focus was through studies of bisphosphonates for the treatment of 
hypercalcaemia of malignancy which, 30 years ago, was a relatively common, life 
threatening metabolic complication of advanced cancer. Treatments available at the 
time, such as calcitonin, mithramycin and corticosteroids, in addition to intravenous 
rehydration, were all sub-optimal and typically only controlled serum calcium for a 
few days. As a result, there was a major unmet clinical need for a safe and effective 
treatment strategy for hypercalcaemia of malignancy.  




 with some success but the 
restoration of normocalcaemia was sub-optimal and short-lived. Initially, there were 
concerns that potent intravenous bisphosphonates, such as pamidronate (often 
referred to as APD in the 1980s and 90s),
9
 would cause renal damage and for this 
reason, experience was limited to the daily administration of very low doses 
(pamidronate 1mg), alongside vigorous intravenous hydration, given until the 
calcium normalised.
10
 Subsequently during the 1980s, several oncology research 
teams, including myself as a young research fellow at the time, cautiously and on the 
back of warnings from Olaf Bijvoet and colleagues with considerable trepidation, 
tested larger single doses of 5mg, 15mg and 30mg in patients with hypercalcaemia. 
Fortunately, significant renal adverse events were not seen and these single 
treatments were shown to be both safe and effective, restoring normocalcaemia in 
around three quarters of treated patients for a median duration of 2-3 weeks.
11,12
 
Some years later, regulatory approval in both Europe and North America of 
pamidronate at doses of 60-90mg
13
 as a single infusion was granted and almost 
overnight, alongside intravenous fluids, the standard of care for hypercalcaemia of 
malignancy was changed. 
 
Prevention of skeletal morbidity in metastatic breast cancer 
In the 1980s, small trials with oral clodronate
14
 and oral pamidronate
15
 had also 











the group led by Inkeri Elomaa in Finland even suggested a survival benefit from the 
use of daily oral clodronate in women with metastatic bone disease,
14
 although this 
was probably just a chance observation associated with the small number of patients 
included in the study. However, excited by these preliminary results, and despite any 
meaningful commercial interest from the pharmaceutical industry which at that time 
was not seriously considering a role for bisphosphonates in malignant disease, a 
number of European investigators tested intermittent intravenous pamidronate as a 
palliative treatment approach in women with bone metastases from breast 
cancer.
16-19  
In these studies heavily pre-treated patients with metastatic bone 
disease received infusions of pamidronate without background endocrine or 
cytotoxic treatments and the effects on bone imaging, bone biomarkers and pain 
observed in much the same way as one would in a phase II study evaluating efficacy 
of a more conventional anticancer treatment.  
Our early experience at Guy’s Hospital in the first of these studies showed clinically 
useful effects on bone pain from metastatic disease with pamidronate 30mg 
administered every two weeks.
16
 In addition, two of the first few patients treated 
were noted to have developed radiographic sclerosis of lytic metastatic lesions on 
follow-up radiographs. At the time the imaging response was interpreted as a 
possible anti-tumour effect of the bisphosphonate resulting in the healing of 
osteolytic bone metastases, created considerable international interest in this novel 
approach to the treatment of bone metastases, and encouraged recruitment to the 
ongoing studies within Europe.
17-19
 With hindsight however, this interpretation was 
almost certainly not correct, but rather reflected the consequences of the 
uncoupling of bone resorption and formation with specific inhibition of tumour 
induced osteolysis by pamidronate alongside continued increased new bone 
formation. 
 
Initially Ciba Geigy, the manufacturer of pamidronate at the time, had little interest 
in the commercial development of pamidronate. However, following the publication 
of our experience and other pilot studies in advanced breast cancer confirming the 
beneficial effects of pamidronate on pain from bone metastases,
16,19
 the company 
initiated large randomised clinical trials in the early 1990s. These evaluated the 
effects of intravenous pamidronate every 3-4 weeks on a new endpoint termed 
skeletal related events (SREs) proposed by the company to try and objectively 
measure the effects of treatment on the skeletal morbidity associated with 
metastatic bone disease in breast cancer
20,21
 or myeloma bone disease.
22
 SREs 
included radiotherapy to bone for pain relief or structural damage, pathological 
fracture, spinal cord compression, orthopaedic intervention for impending or actual 
fracture and hypercalcaemia and were accepted by the regulatory authorities as 











These large phase III studies, conducted largely in the United States,
20-22
 and a similar 
trial with oral clodronate,
23 
showed significant benefits in breast cancer with a 25-
30% reduction in risk of SREs over and above standard anticancer and supportive 
care treatments, and associated with an improvement in bone pain, reduced 
analgesic consumption and improved quality of life.
20-22
   
The evaluation of these studies by the regulators in the United States are of historic 
interest and perhaps illustrate the relative subjectivity of the regulatory processes at 
the time. In the studies with pamidronate, the benefits in terms of reducing the 
proportion of patients experiencing an SRE were particularly striking in the patients 
treated with chemotherapy
20
 and the Oncology Drugs Advisory Committee ODAC) 
had no problem recommending regulatory approval to the Food and Drugs 
Administration (FDA). However, the primary endpoint data in patients receiving 
endocrine treatment,
21
 while consistent with the findings in the chemotherapy 
treated cohort, were only of borderline statistical significance and ODAC was 
uncertain and split 3-3 on whether to recommend approval
24
 until a patient 
advocate on the panel urged the committee to reconsider on the basis that the 
treatment had relatively few side effects and appeared to make a large difference to 
endpoints that really matter to patients such as pain, quality of life and mobility. It 
seemed likely that her viewpoint was influenced by the descriptions of significant 
toxicity associated with the use of a chemotherapy agent, irinotecan, she had 
listened to earlier in the day. Despite the challenging and significant toxicity 
alongside only modest efficacy, ODAC had recommended accelerated approval of 
irinotecan. On reflection ODAC agreed with the patient advocate and, as a result of 
these two trials, intravenous pamidronate became part of standard management for 
patients with bone involvement from breast cancer, irrespective of the underlying 
systemic treatment. One wonders what might have happened if the order of the 
hearings at ODAC that day had been reversed!
 
For clodronate the outcome was less successful. Despite the benefits demonstrated 
by several academic teams of trialists,
14,23,25
 approval in the United States was not 
recommended due to a handful of isolated reports of leukaemia developing in 
patients who had at some time in their clinical course been treated with clodronate. 
The fact that these patients had received many other treatments, including those 
such as melphalan and radiation therapy that are known be carcinogenic, was not 
sufficient to sway the views of the regulators and to this day, although approved in 
Europe, Canada and many other parts of the world, clodronate does not have a 
licence within the United States for any therapeutic indication. 
 





 were developed. Zoledronate is commonly, but 
inappropriately, called zoledronic acid in an attempt to distinguish it from other 











present as anions and not as free acids. Interestingly, potency in laboratory systems 
provided only marginal benefits in the clinic beyond the ability to lower the dose 
administered and, due more to the long biological half-life in bone rather than 
potency per se, extend the interval between treatments. Development of 
zoledronate also began in Europe for hypercalcacaemia
29 
before evaluation for 
prevention of skeletal morbidity from bone metastases.
30
 Oral ibandronate provides 
a particularly useful alternative for patients wishing to avoid treatment by injection
26
 
although in a large randomised study comparing zoledronate and oral ibandronate, 
non-inferiority of the oral option could not be proven.
31
 
In the large phase III registration trials, zoledronate  was compared to pamidronate 
in patients with breast cancer and multiple myeloma
32
 as this was the standard of 
care at the time and compared to placebo in prostate cancer
33
 and other solid 
tumours.
34
 In the breast cancer study, zoledronate was statistically “non-inferior” to 
pamidronate
32
 and, on this basis, was approved by the regulatory agencies 
worldwide for routine clinical use. Again, the regulatory process in the United States 
was interesting. Although the more cautious endpoint of non-inferiority was the 
primary endpoint of the study, the expectation was that the added potency of 
zoledronate would result in superior outcomes with clear benefit in reducing the 
numbers of patients experiencing SREs and prolonging the time to the first SRE. 
However, these outcomes were very similar with the two treatments and the 
discussions with the regulators focussed on validity of the non-inferiority margin 
previously agreed with the FDA as the primary endpoint. This required that the 95% 
confidence intervals for the comparative hazard ratio between the two treatments 
excluded the loss of more than 50% of the benefit achieved with pamidronate in the 
original pamidronate versus placebo studies. Debate as to whether this was 
sufficiently strict (modern non-inferiority trials require preservation of a much 
greater proportion of the standard treatment effect) and whether the populations 
studied were comparable ensued. In the end ODAC were satisfied that the findings 
from the breast cancer trial were meaningful and valid and recommended approval 
for use in this indication as well as other solid tumours (Table 1).
35
 
Longer follow-up of patients in the trial comparing zoledronate to pamidronate, 
coupled with the use of exploratory complex multiple event analyses, showed 
statistically significant superiority of zoledronate over pamidronate for breast cancer 
patients with a 20% reduction in the overall risk of SREs
36
 and zoledronate became 
the standard of care throughout most of the world for patients with breast cancer 
and bone metastases based more in most centres on the convenience of a short 
infusion time rather than because of the marginal greater efficacy.  
Subsequently denosumab was introduced with much of the early development work 
led from Europe.
37
 In the phase III registration trials, denosumab was shown to be 
marginally more effective in reducing skeletal morbidity
38











observed in the pre-bisphosphonate era of 3-4 per year has now fallen to <1 per 
year. Additionally, the severity of the residual SREs that do occur is generally mild 
with very few episodes nowadays of spinal cord compression, long bone fracture or 
hypercalcaemia in the context of metastatic breast cancer.
39
  
As a class, bisphosphonates (and indeed denosumab also) are well tolerated and the 
risk-benefits clearly favour use in metastatic bone disease, However, following case 
reports in 2003
40
 and subsequent small case series of patients
41
 developing 
osteonecrosis of the jaw (ONJ) associated with the use of a bisphosphonate, a 
degree of hysteria developed surrounding this adverse event. For a time, fear of ONJ 
threatened to limit the use of these important treatments. However, with careful 
monitoring of patients, good oral and dental health and minimising of surgical 
procedures on the jaw and dental extractions,
42
 the risk of developing ONJ with the 
relatively intensive dosing schedules used in advanced cancer is low at around 1% 
per year on treatment,
43
 and considerably less than this for patients receiving 
bisphosphonates in the adjuvant setting or to prevent treatment induced bone loss.
 -
44,45
 Such risks are clearly dwarfed by the 30-50% reduction in SRE and most breast 
cancer patients and their treating specialists recognise the benefits and accept the 
small level of risk for ONJ associated with treatment. 
 
Metastasis prevention 
Because of their profound effects on bone physiology, there has been interest for 
several decades in the potential use of bisphosphonates to modify the process of 
metastasis and have effects on important clinical outcomes such as disease 
recurrence and survival.
46
 The potential benefits of bone-targeted treatments on the 
clinical course of breast cancer have been the subject of clinical trials for more than 
20 years.  
Ingo Diel and colleagues published the first meaningful randomised trial of adjuvant 
bisphosphonates in early breast cancer in 1998.
47
 Patients were selected on the basis 
of the presence of disseminated tumour cells (DTC) in bone marrow aspirates taken 
at the time of surgery but without overt metastases identified on imaging tests. 
Patients with DTC detected by immunocytochemistry have a relatively poor 
prognosis with 2-3 times increased risk for subsequent relapse compared with DTC 
negative patients.
48
 In their randomised trial, Diel and colleagues showed fewer 
relapses, especially in bone and improved survival in the patients treated with daily 
oral clodronate. Similar positive findings with oral clodronate were reported a few 
years later by Trevor Powles and colleagues in a larger placebo-controlled trial.
49
 
However a study from Finland   reported a possible adverse effect of clodronate on 
outcomes.
50
 These varying results were at the time somewhat difficult to reconcile 











In 2009, more than a decade later, a potentially practice changing study conducted 
by the Austrian Breast Cancer Study Group (ABCSG)-12 was reported. This academic 
study showed significant benefit from the addition of six monthly zoledronate when 
added to endocrine therapy that included ovarian suppression for premenopausal 
women with oestrogen receptor (ER) positive disease.
44
 For the first time, breast 
oncologists started to take an interest in the concept of modifying the host 
microenvironment as an alternative or addition to conventional tumour cell directed 
therapies such as chemotherapy and targeted treatments such as endocrine 
treatments for ER+ disease and trastuzumab for HER2+ disease. Indeed, the ABCSG-
12 study was perhaps over-interpreted and some oncologists started, without 
regulatory approval, to recommend the use of adjuvant bisphosphonates in their 
young women with breast cancer, focussing on the fact that the study participants 
were premenopausal at diagnosis but ignoring the fact that they were all rendered 
postmenopausal through the use of ovarian suppression therapy.  However, a year 
later, the first results from the larger AZURE study
51
 brought that to a sudden stop. 
The AZURE study had been designed by a team of international investigators led 
from the University of Sheffield. The trial was funded through an unrestricted grant 
from Novartis and run as an academic study.  The study had much broader inclusion 
criteria than ABCSG-12, including pre and postmenopausal women and both ER+ and 
ER- stage II/III breast cancer. It also utilised a more intensive treatment regimen of 
zoledronate with 3-4 weekly infusions for the first 6 treatments, typically 
administered alongside adjuvant chemotherapy, followed by a maintenance dose 
every 3-6 months for 5 years resulting in  a total of 19 infusions of zoledronate 4mg. 
Somewhat surprisingly in light of the ABCSG-12 findings and most of the experience 
with daily oral clodronate, the study showed no benefit on recurrence or survival in 
an intention to treat (ITT) analysis either at the time of the initial analysis
51
 or at later 
planned follow-up analyses.
52
 However, the AZURE study did identify potential 
benefits in a pre-defined subgroup of patients who were postmenopausal at the 
time of study entry and, taken with the benefits seen in ABCSG-12 and several bone 
protection studies
44,45,53
 conducted in postmenopausal women, suggested that any 
benefits associated with the use of adjuvant bisphosphonates were perhaps 
restricted to women who had low levels of reproductive hormones due to either 
natural age related menopause or ovarian function suppression.  
This hypothesis was supported by studies in mouse models of metastasis in which 
the reduction in metastasis and survival of animals treated with zoledronate were 
much greater in mice that had previously undergone oophorectomy.
54
 In an initiative 
co-ordinated by the Early Breast Cancer Clinical Trials Group (EBCTCG) to investigate 
this hypothesis in patients, data from randomised trials that had evaluated the effect 
of an adjuvant bisphosphonate on breast cancer outcomes were collated from 











detailed individual patient meta-analysis of 18,766 women included in a total of 36 
randomised trials comparing the administration of a bisphosphonate (any type and 
duration) versus none in women with early breast cancer.
55
 A total of 3,453 breast 
cancer recurrences and 2,106 breast cancer deaths were available, enabling the 
meta-analysis to demonstrate important clinical benefits that could not be reliably 
identified in individual trials.  
The meta-analysis showed overall (Figure 1), including all randomised patients, that 
bisphosphonates reduced first distant recurrence in bone (risk ratio (RR)=0.83; 
95%CI 0.73-0.94, 2p=0.004) and confirmed a significant interaction between 
treatment efficacy and menopausal status. There were no demonstrable benefits in 
any disease outcome seen in the 6,171 premenopausal women but, in the 11,767 
postmenopausal women, highly significant and clinically important reductions in 
bone recurrence (RR=0.72; 95%CI 0.60-0.86, 2p=0.0002) and breast cancer mortality 
(0.82; 95%CI 0.73-0.93, 2p=0.002) with follow-up out to 10 years after randomisation 
were seen.
55
 Benefits appeared to be of similar magnitude across different biological 
subgroups of breast cancer (ER + and ER-) and independent of the bisphosphonate 
used in the trials which included daily oral clodronate, daily oral ibandronate and 
intermittent intravenous zoledronate. However, there are no randomised data 
available on the efficacy of osteoporosis dosing of alendronate or risedronate and 
extrapolation of the effects to these low dose oral schedules is not possible.  
The mechanisms underlying the relationships between metastasis prevention and 
ovarian function are not well understood. Preliminary data, however, indicate that 
the efficacy of adjuvant bisphosphonates may be related to the expression of the 
transcription factor MAF within the primary tumour. In the AZURE trial, highly 
significant improvements in recurrence and survival with zoledronate were seen in 
the 80% of patients with MAF negative tumours (irrespective of menopausal status) 
while in the 20% with over-expression of MAF, worse outcomes were seen especially 
in young patients who were still menstruating at the start of treatment.
56,57
 MAF 
regulates many processes of potential relevance to metastasis including adhesion 
molecules, PTHrP and the activity of  T lymphocytes.57,58 Validation of these 
observations are ongoing.  
The reduction in 10-year breast cancer mortality equates to around 10,000 lives 
saved within the 28 European Union countries. Despite the lack of regulatory 
approval for bisphosphonate use in the setting of early breast cancer, these findings 
are changing clinical practice and, increasingly, the use of adjuvant bisphosphonates 
is now recommended in clinical guidelines both in Europe and North America and, in 
many centres, become  part of routine adjuvant therapy for postmenopausal women 
with early breast cancer deemed at intermediate to high risk for recurence.
59,60
 
The potential disease modifying effects of denosumab have also been assessed in 











in the ABCSG-18 study that was designed primarily to assess the ability of 
denosumab to prevent fractures associated with the use of aromatase inhibitors in 
ER+ postmenopausal women with breast cancer.
61
 A significant improvement in 
disease-free survival with denosumab was reported, but this was mainly due to 
reductions on second non-breast primary cancers and deaths without recurrence 
rather than prevention of breast cancer recurrences; observations that seem 
biologically implausible.  
In the DCARE trial, 4509 women with early breast cancer at moderate to high risk for 
recurrence were randomised to receive either denosumab or placebo, but using a 
more intensive treatment schedule than in the ABCSG-18 study of denosumab 
120mg every 3-4 weeks for 6 months and then continued every 3 months for a total 
duration of 5 years.
62
 Denosumab had no significant effect on the primary endpoint 
of bone metastasis free survival  (HR=0·97, 95%CI 0·82–1·14; p value=0·70). 
Additionally, disease-free and overall survival were unaffected by the addition of 
denosumab to standard adjuvant breast cancer treatments, either in the study 
population as a whole or in the postmenopausal subgroup; findings that clearly 
contrasted to those seen with adjuvant bisphosphonates. The apparent differences 
between adjuvant denosumab and bisphosphonates suggest that the benefits of the 
latter perhaps relate more to their broader biological effects on other aspects of the 
metastatic process rather than their primary effects on bone cell function. Effects on 
tumour cell adhesion and migration, angiogenesis and immune effects in animal 
models, as well as clearing of DTC from the bone marrow with bisphosphonates, 
have all been demonstrated.
46
 On the other hand, any effects denosumab might 
have on tumour cells would likely be restricted to RANK-expressing cells which 
constitute only a small proportion of breast cancers.
63 
Finally, the knowledge obtained from studies of bone-targeted treatments in 
osteoporosis has been applied to the cancer setting. Many patients, notably breast 
cancer patients receiving aromatase inhibitors or experiencing chemotherapy 
induced premature menopause experience rapid bone loss due to the resultant 





 have been shown to prevent 
this treatment induced bone loss; the effects of denosumab on fracture incidence 
were particularly impressive with a 50% reduction in fracture risk.
64
 
In conclusion, the use of bisphosphonates has had profound beneficial effects on the 
clinical course of breast cancer, preventing recurrence in some situations and 
reducing skeletal morbidity and the clinical consequences of metastatic bone disease 
for those with incurable advanced disease. However, the development pathway has 
been long, somewhat tortuous and, at times, unconventional, reliant largely on 
academic innovation at a time when drug development was less structured and rigid. 











necessary but, much of what we have learnt over the past 30 years might not have 
occurred under the current approach of tightly focussed and rigid pharma-driven 
drug development. 
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Table 1: Key results from studies with bisphosphonates to prevent skeletal-related 



























43% vs 56% 
56% vs 67% 
30% vs 50% 
43% vs 45% 
NE 
51% vs 62% 
NE 
NE 
399 vs 213 days 
317 vs 210 days 
NR vs 364 days 
310 vs 174 days 
632 vs 454 days 
354 vs 232 days 
NR vs 804 days 
SMR - 219 vs 305  
Improved QOL and pain 
Improved QOL and pain 
Improved pain 
20% risk reduction for SRE 
SMPR - 0.99 vs 1.15  
SMPR - 1.19 vs 1.48  









NE, not evaluable; NR, not reached; QOL, quality of life; SRE, skeletal related event; SMR, 













Bisphosphonates have transformed the care of breast cancer patients with bone 
metastases and are firmly established as a key element of standard treatment 
throughout the course of the disease. 
In postmenopausal women with early breast cancer, bisphosphonates reduce bone 
recurrences by about one quarter and cancer deaths by one sixth. 
Due to limited understanding of the underlying biology of metastasis and the 
limitations of animal model systems, the clinical development of bisphosphonates in 
oncology has been relatively slow and complex and largely reliant on discoveries and 
innovation from academic groups rather than “big pharma”. 
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